Treating neurodegenerative conditions
AssigneeMax-Planck-Gesellschaft Zur Forderungder Wissenschaften, E.V.
InventorsEckhard Mandelkow, Eva-Maria Mandelkow, Jacek Biernat, Martin Bergen, Marcus Pickhardt
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of compounds capable of inhibiting protein aggregate formation and capable of depolymerising protein aggregates for the preparation of a pharmiaceutical composition for treating neurodegenerative conditions such as Alzheimer disease.
Claims44
A method for treating a neurodegenerative condition comprising administering a pharmaceutical composition comprising a therapeutically effective amount of a compound that inhibits protein aggregate formulation and depolymerizes protein aggregates.
A genetically modified cell line, wherein tau gene expression can be induced.
(canceled)
(canceled)
A transgenic non-human animal which expresses a mutant of tau that polymerize in neurons into aggregates.
(canceled)
A method for identifying an agent capable of inhibiting protein aggregate formation or capable of depolymerising protein aggregates, comprising contacting cells with the agent and determining a decrease in protein aggregate formation or a depolymerisation of protein aggregates, wherein the cells express a mutant of tau in an inducible fashion that polymerizes in the cell into aggregates which can be visualized by thioflavine S.
Dependencies are inferred from the claim text.